Skip to main content
OpenTrials

Clinical trial condition

Lymphatic Diseases

Explore clinical trials studying Lymphatic Diseases. Study availability and eligibility vary by location and protocol.

8,967 public trials 1,828 recruiting studies
Refine in advanced search Browse all conditions

Lymphatic Diseases trial results

Active, Not Recruiting

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

NCT01695941

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +12 more
Locations
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, United States
  • Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
  • Montefiore Medical Center - Moses Campus The Bronx, New York, United States
  • Fox Chase Cancer Center Philadelphia, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

NCT02180711

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Research Site Tucson, Arizona, United States
  • Research Site Downey, California, United States
  • Research Site Duarte, California, United States
  • Research Site Fountain Valley, California, United States
View all 29 locations
View Trial Details
Active, Not Recruiting

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

NCT04623541

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +17 more
Locations
  • O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of California Davis Medical Center Sacramento California City, California, United States
  • City of Hope National Medical Center Duarte, California, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
View all 81 locations
View Trial Details
Active, Not Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +16 more
Locations
  • The University of Arizona Cancer Center - North Campus /ID# 242219 Tucson, Arizona, United States
  • Yale University School of Medicine /ID# 242089 New Haven, Connecticut, United States
  • Christiana Care Health Service /ID# 242301 Newark, Delaware, United States
  • Tampa General Hospital /ID# 246748 Tampa, Florida, United States
View all 76 locations
View Trial Details
Active, Not Recruiting

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

NCT04542824

Conditions
Chronic Disease, Diffuse Large B Cell Lymphoma, Disease Attributes, +25 more
Locations
  • Tohoku University Hoaspital Sendai, Miyagi, Japan
  • Aichi Cancer Center Hospital Aichi, Japan
  • NHO Nagoya Medical Center Aichi, Japan
  • National Cancer Center Hospital East Chiba, Japan
View all 15 locations
View Trial Details
Active, Not Recruiting

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

NCT03625037

Conditions
Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Chronic Disease, DLBCL, +26 more
Locations
  • Arizona Mayo Clinic Phoenix, Arizona, United States
  • University of California at San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
View all 85 locations
View Trial Details
Active, Not Recruiting

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04408638

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Community Cancer Institute (CCI) Fresno, California, United States
  • Baptist - MD Anderson Cancer Center Jacksonville, Florida, United States
  • University of Maryland Medical Center Baltimore, Maryland, United States
View all 63 locations
View Trial Details
Active, Not Recruiting

Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

NCT03179917

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations
  • University of Miami Miami, Florida, United States
  • Memorial Sloan Kettering at Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
View Trial Details

Related conditions